Sepsis Diagnostics Market Size

  • Report ID: 4869
  • Published Date: May 09, 2025
  • Report Format: PDF, PPT

Sepsis Diagnostics Market - Historic Data (2019-2024), Global Trends 2025, Growth Forecasts 2037

Sepsis Diagnostics Market in 2025 is evaluated at USD 2.74 billion. The global Market size was over USD 2.5 billion in 2024 and is anticipated to witness a CAGR of around 12%, crossing USD 10.91 billion revenue by 2037. North America is estimated to garner USD 4.25 billion by 2037, attributed to developed healthcare infrastructure and the increasing incidence of sepsis and infectious diseases.

The growth of the market can be attributed to the increasing number of elderly people who are prone to sepsis. Further, the growing technological advancements in the field of sepsis diagnostics are expected to add to the market growth. The United States Food and Drug Administration, FDA, granted marketing authorization to Immunoexpress Inc.'s SeptiCyte RAPID in December 2021. In October 2021, Prenosis Inc. extended an existing agreement with Roche Diagnostics to accelerate the clinical diagnosis of sepsis. Prenosis, Inc. is a precision diagnostic company that uses AI in order to help diagnose patients more accurately.

In addition to these, factors that are believed to fuel the growth of sepsis diagnostics market include the increase in sepsis cases, the increased burden of hospital-acquired infections, the rising number of pneumonia cases, a higher level of sepsis treatment, and an increase in funding for research related to sepsis. Increased use of sepsis diagnostic products is expected to contribute to market growth. In addition, a new intervention to actively prevent, treat and evaluate sepsis in pregnant women was funded by more than GBP 3 million in June 2021.


Sepsis Diagnostics Market Size

Browse key industry insights with market data tables & charts from the report:

Frequently Asked Questions (FAQ)

Sepsis Diagnostics Market in 2025 is evaluated at USD 2.74 billion.

The global market size was over USD 2.5 billion in 2024 and is anticipated to witness a CAGR of around 12%, crossing USD 10.91 billion revenue by 2037.

North America is estimated to garner USD 4.25 billion by 2037, attributed to developed healthcare infrastructure and the increasing incidence of sepsis and infectious diseases.

The major players in the market include BioMérieux SA, Becton, Dickinson and Company, Thermo Fisher Scientific, Inc., F. Hoffmann-La Roche AG, Danaher Corporation (Beckman Coulter, Inc.), Cepheid, Beckman Coulter, Inc., Amara Health Analytics, Wolters Kluwer N.V., Cerner Corp.
Inquiry Before Buying Request Free Sample PDF
footer-bottom-logos